10mM in DMSO pour les flux de travail chromatographiques et analytiques sensibles nécessitant une interférence de ligne de base minimale.
Store at -80°C Expédition Dry ice packs + Cold packs. Consultez le COA spécifique au lot pour les spécifications exactes.
SDS, COA, fiche technique et fiche de spécifications disponibles au téléchargement. COA spécifique au lot accessible via la recherche par numéro de lot.
Cité dans 0 publications à comité de lecture couvrant la chromatographie, la synthèse organique et les réactions de couplage croisé.
Apinocaltamide (ACT-709478) is a potent, selective, orally active, and brain penetrating T-type calcium channel blocker. ACT-709478 is used in the research of generalized epilepsies
In Vitro
Apinocaltamide (Compound 66b) blocks Ca v 3.1, Ca v 3.2, Ca v 3.3, Ca v 1.2 with IC 50 s of 6.4, 18, 7.5 and 2410 nM, respectively. Apinocaltamide blocks recombinant channel hCa v 3.3 potently with marked voltage-dependency (K r ≈1500 nM and K i ≈20 nM). Apinocaltamide blocks currents through hK v 11.1-hERG channels with an IC 50 of 5.5 μM. Apinocaltamide also inhibits P450 enzymes with IC 50 s of 14, 15, 22, 25, 51 and 52 μM for CYP2C8,CYP2D6 CYP2C9, CYP2C19, CYP3A4, and CYP2B6, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Apinocaltamide (Compound 66b, 100, 300 mg/kg, p.o., measured 12 hours later) potently decreases the cumulative duration of absence-like seizures in mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male juvenile DBA/2J mice (22-24 days old) Dosage: 100, 300 mg/kg, 1 hour or 3 hours before exposure to the stimulus. Administration: P.O., for 12 hours Result: Decreased the cumulative duration of absence-like seizures over the next 12 h period by 93%.
IC50& Target:Ca v 1.2 2410 nM (IC 50 ) Ca V 3.1 6.4 nM (IC 50 ) Ca v 3.2 18 nM (IC 50 ) Ca V 3.3 7.5 nM (IC 50 )
Document complet couvrant les dangers, la manipulation, le stockage et la conformité réglementaire.
<<<<<<< HEAD Télécharger la SDS → ======= Télécharger la SDS → >>>>>>> release248-p3Données qualité spécifiques au lot. Saisissez votre numéro de lot pour récupérer le COA exact.
Rechercher le COA →Résumé de référence rapide des spécifications et applications du produit.
Voir la fiche technique →Attributs de qualité complets et critères d'acceptation pour cette qualité.
Voir la fiche de spécifications →| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Article |
|---|---|---|---|
 J2613710 | Certificate of Analysis | Oct 16, 2026 | A655794 |
